Skip to main content
. 2024 Feb 1;18:306–321. doi: 10.1016/j.xjon.2024.01.014

Figure E3.

Figure E3

A, P-stat3 expression with increasing losartan (H441, ∗P = .024; H358, ∗P = .000; H1299, ∗P = .000; SW1573, ∗P = .000; TC-1, ∗P = .032). B, Stat3 expression with increasing losartan (H441, ∗P = .030; H358, ∗P = .032; H1299, ∗P = .015; SW1573, ∗P = .040; TC-1, ∗P = .036). C, P-protein kinase B (AKT) expression with increasing losartan (H441, ∗P = .033; H358, ∗P = .047; H1299, ∗P = .002; SW1573, ∗P = .000; TC-1, ∗P = .024). D, AKT expression with increasing losartan (H441, ∗P = .003; H358, ∗P = .032; H1299, ∗P = .000; SW1573, ∗P = .005; TC-1, ∗P = .043). E, program death ligand 1 (PD-L1) expression with increasing losartan (H441, ∗P = .034; H358, ∗P = .005; H1299, ∗P = .038; SW1573, ∗P = .005; TC-1, ∗P = .005). F, Body weight of nude mice with SW1573. G, Body weight of C57BL/6 mice with TC-1. H, Vimentin, P-stat3, Stat3, P-AKT, AKT, and PD-L1 expression in mice with lung cancer.